One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC ...

The FDA updated a warning on the label of esketamine nasal spray (Spravato ... A psychiatrist explains the difference between "normal" anxiety and an anxiety disorder. (Washington Post) Brief ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression ...

Results, published in CNS Spectrums, showed a significant improvement in symptoms for those taking a new OAD with esketamine ...

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

Janssen, which is Johnson & Johnson’s pharma unit, submitted a filing to the European Medicines Agency for esketamine nasal spray, which is designed to help people with treatment-resistant ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...